What is Cardiovascular Systems' stock symbol?
Cardiovascular Systems trades on the NASDAQ under the ticker symbol "CSII."
Where is Cardiovascular Systems' stock going? Where will Cardiovascular Systems' stock price be in 2017?
6 analysts have issued twelve-month target prices for Cardiovascular Systems' shares. Their predictions range from $30.00 to $40.00. On average, they anticipate Cardiovascular Systems' share price to reach $33.40 in the next twelve months.
When will Cardiovascular Systems announce their earnings?
Cardiovascular Systems is scheduled to release their next quarterly earnings announcement on Tuesday, May, 2nd 2017.
What are analysts saying about Cardiovascular Systems stock?
Here are some recent quotes from research analysts about Cardiovascular Systems stock:
- Needham & Company LLC analysts commented, "CSII's F2Q17 revenue and EPS beat consensus. However, F3Q17 revenue and EPS guidance was slightly below consensus. CSII continued on its path to profitability with adjusted EBITDA of $4.6M and cash flow of $5.9M (excluding a one-time $10M payment from Medikit). While revenue growth exceeded 20% Y/ Y for the first time in six quarters, we note that F2Q17 marked the bottom for its revenue growth comps. And although CSII's revenue growth may slow as it faces increasingly difficult comps over the next few quarters, we think it can sustain doubledigit revenue growth. We think that F3Q17 guidance is conservative, and we expect additional revenue and EBITDA upside. Reiterate Buy rating." (1/26/2017)
According to Zacks Investment Research, "In the last six months, Cardiovascular Systems has steadily outperformed the broader medical product market trend with respect to price performance. Recently, the company posted solid first-quarter fiscal 2016 performance which further improved the trend. We are encouraged by the company’s improving operating expense scenario which was the main factor for the year-over-year improvement in the loss figure. Cardiovascular Systems stands to gain from several favorable trends in the peripheral artery diseases as well coronary artery disease markets. Moreover, management is optimistic about engineering enhancements and higher production volumes which may continue to reduce unit cost in the quarters ahead. Besides, the completion of a settlement agreement with the Department of Justice is an upside. On the flip side, the company operates in the competitive medical device industry, which gets significantly affected by new product introductions." (1/17/2017)
Leerink Swann analysts commented, "We view this quarterly performance as certainly positive and encouraging, again perhaps suggesting that the business — notably the salesforce — has stabilized, execution has improved, and CSII is back on an accelerating sales growth trajectory. But given the recent history of sales force disruptions, we’re inclined to wait for another quarter to see tangible benefits and further proof that the salesforce stabilization is sustainable — as well as the naming of a new permanent CEO — before leaving the sidelines. Workforce Reduction Likely More Back-Office Related. In F3Q16, CSII will take a $4.5M one-time restructuring charge tied to the 8% workforce reductions. We checked with the company last night, and while details were sparse, it appears the cuts are broad-based across the organization and efforts were already underway to implement these workforce reductions in the most recent quarter. But with the recent efforts to stabilize the salesforce, we’re inclined to believe the cuts are more heavily weighted towards back-office operations. DOJ Overhang also Removed. In late March, CSII also reached an agreement in principle with the DoJ to settle claims underlying the ongoing investigation into sales practices." (4/1/2016)
Who owns Cardiovascular Systems stock?
Cardiovascular Systems' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Champlain Investment Partners LLC (5.07%), Frontier Capital Management Co. LLC (2.62%), State Street Corp (1.80%), Castleark Management LLC (1.10%), Thrivent Financial for Lutherans (0.89%) and Two Sigma Investments LP (0.70%). Company insiders that own Cardiovascular Systems stock include Alexander Rosenstein, Brent G Blackey, Camber Capital Management Llc, David Martin, Edward M Brown, Kevin J Kenny, Laura Gillund, Laurence L Betterley, Paul A Koehn, Robert J Thatcher and Scott R Ward.
Who sold Cardiovascular Systems stock? Who is selling Cardiovascular Systems stock?
Cardiovascular Systems' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Numeric Investors LLC, Renaissance Technologies LLC, Bogle Investment Management L P DE, Menta Capital LLC, GSA Capital Partners LLP, Two Sigma Investments LP and Frontier Capital Management Co. LLC. Company insiders that have sold Cardiovascular Systems stock in the last year include Alexander Rosenstein, Camber Capital Management Llc, Edward M Brown, Kevin J Kenny, Laura Gillund, Laurence L Betterley and Paul A Koehn.
Who bought Cardiovascular Systems stock? Who is buying Cardiovascular Systems stock?
Cardiovascular Systems' stock was acquired by a variety of institutional investors in the last quarter, including Champlain Investment Partners LLC, Allianz Asset Management AG, Thrivent Financial for Lutherans, A.R.T. Advisors LLC, Marshall Wace LLP, State Street Corp, AQR Capital Management LLC and Teachers Retirement System of The State of Kentucky. Company insiders that have bought Cardiovascular Systems stock in the last two years include Brent G Blackey, Camber Capital Management Llc and Scott R Ward.
How do I buy Cardiovascular Systems stock?
Shares of Cardiovascular Systems can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Cardiovascular Systems stock cost?
One share of Cardiovascular Systems stock can currently be purchased for approximately $27.81.